Redeye: RLS Global Q4 2022 - No surprises – but expectations of an eventful 2023
Redeye provides an update in relation to RLS’ Q4 2022 report. The report did not include any major surprises in our view; however, we expect quarterly reports to become more interesting as we expect sales to ramp up during 2023. We make some changes in our OPEX assumptions, include a future capital raising, and increase the WACC to 13.5% (12.5%) because of an updated Redeye Rating. The changes result in a new fair value range.
Read more and download the Research Update.
Follow companies at Redeye to receive the latest equity research within Life Science and Technology.
This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/